(Nasdaq:ARNA) Arena Pharmaceuticals, Inc. Sets 52 Week High Record

Arena Pharmaceuticals, Inc. (Nasdaq:ARNA)

May 15th, 2019

Amidst rising markets Arena Pharmaceuticals, Inc. finished up $1.11 Wednesday, a 2.02% jump, closing at $55.96. Furthermore it hit a new 52 week high of $56.04.

ARNA outperformed the rest of the Healthcare sector which went up 0.27% today.

Expectations from 10 analysts indicates that Arena Pharmaceuticals, Inc. could go up significantly (24.86%), while Finbox has calculated (with medium uncertainty) a fair value price of $52.23.

Market Sectors

The market sectors were mixed Wednesday with a majority of the sectors trending up. Communication Services saw the biggest increase of the day (2.11%), while Financials saw the biggest drop (-0.48%). Information Technology has seen the biggest year-to-date gain at 21.11%.

Communication Services saw the biggest turnaround from its 5-day performance of -0.19%, as it went up 2.11%. Utilities saw a turn around from its 5-day performance of 1.74% trading down -0.13%.

Sector Breakdown

  • Communication Services went up with a 2.11% change.
  • Information Technology went up with a 0.98% change.
  • Consumer Staples went up with a 0.80% change.
  • Consumer Discretionary went up with a 0.78% change.
  • Real Estate went up with a 0.64% change.
  • Energy went up with a 0.46% change.
  • Healthcare went up with a 0.27% change.
  • Industrials went up with a 0.12% change.
  • Utilities went down with a -0.13% change.
  • Materials went down with a -0.24% change.
  • Financials went down with a -0.48% change.

Arena Pharmaceuticals, Inc. Info

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn’s disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

All amounts in USD unless otherwise indicated

ARNA daily update
ARNA daily update

Via UnSplash

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

Tell us what you think